Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Condition:   Type 2 Diabetes Mellitus Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Empagliflozin;   Drug: Placebo Sponsor:   Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials